 |
 |

S35-Labeled Bendroflumethiazide in Human BeingsClinical Studies
HERBERT R. BRETTELL, MD;
JAMES G. SMITH, MD;
JERRY K. AIKAWA, MD
Arch Intern Med. 1964;113(3):373-377.
 |
 |
| Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings. |
|
 |
 |
Bendroflumethiazide (Naturetin)-3-benzyl-3,4-dihydro-6-(trifluoromethyl)-2H-1,2, 4-benzothiadiazine-7-sulfonamide 1,1-dioxide —is a nonmercurial diuretic agent of the benzothiadiazine group, which is effective clinically in the treatment of edema and hypertension.1-5 We have previously studied 6,7 the renal excretion of chlorothiazide and hydrochlorothiazide labeled with radioactive carbon (C14) in normal subjects and in patients with various medical diseases associated with the retention of water and electrolytes. The cumulative renal excretion of radioactivity was lower in patients with cardiac, renal, and hepatic diseases than in normal subjects. The amount of radioactivity recovered in the urine appeared to be inversely proportional to the severity of the disease.
In the present study, S35-labeled bendroflumethiazide was administered orally or intravenously to normal subjects and patients with cardiac, renal, and hepatic diseases. The cumulative renal excretion of radioactivity was compared with that of chlorothiazide and hydrochlorothiazide.
Material and Methods
Material.
—A total of 23 studies were performed in
. . . [Full Text PDF of this Article]
Author Affiliations
DENVER
From the Department of Medicine, University of Colorado School of Medicine.
Footnotes
Received for publication July 26, 1963; accepted Aug 30.
With the technical assistance of Jacqueline Z. Reardon, BA.
This work was supported by a grant-in-aid from the Squibb Institute for Medical Research.
CiteULike Connotea Del.icio.us Digg Reddit Technorati Twitter
What's this?
|